Loading
A phase 1/2 trial of BT-001 run by Transgene, terminated.
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04725331 by Transgene, with 31 participants enrolled, started 2021-02-25. Conditions recorded: Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer and Non Small Cell Lung Cancer. Interventions recorded: BT-001 and Pembrolizumab [KEYTRUDA®].
Shares BioInvent International, Melanoma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioInvent International, Metastatic cancer (cancer that has spread), Non-small-cell lung cancer and the tag pipeline.
Shares Merkel cell carcinoma, Sarcomas (soft tissue, bone, GIST), Non-small-cell lung cancer and the tag pipeline.
Shares Transgene, Non-small-cell lung cancer and the tag pipeline.
Shares Transgene and the tag pipeline.
Shares BioInvent International, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST), Triple-negative breast cancer (TNBC), Non-small-cell lung cancer and the tag pipeline.
Shares Transgene, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/